A5062483085- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Systems, Economic Evaluations, Quality of Life
- Nutritional Studies and Diet
- Birth, Development, and Health
- Pregnancy and preeclampsia studies
- Cardiovascular Issues in Pregnancy
University of Oslo
2021-2025
Oslo University Hospital
2021-2025
Background and aimsWomen with heterozygous familial hypercholesterolemia (FH) are recommended to initiate statin treatment at the same age as men (from 8 10 years of age). However, statins contraindicated when pregnancy is planned, during breastfeeding. The aim study was determine duration pregnancy-related off-statin periods breastfeeding in FH women.MethodsA cross-sectional using an anonymous online self-administered questionnaire conducted. Women were recruited through Lipid Clinics...
Introduction Familial hypercholesterolaemia (FH) is a common genetic condition causing elevated low-density lipoprotein cholesterol levels, which increases the risk of premature atherosclerotic cardiovascular disease. Little currently known about how persons with FH are counselled by their healthcare professionals regarding pregnancy and breastfeeding, impacts partner relationship family planning. Current guidelines advise interrupting most cholesterol-lowering medication during conception,...
Early and lifelong treatment is essential in patients with familial hypercholesterolaemia (FH) due to genetically elevated low-density lipoprotein cholesterol (LDL-C) from the first years of life. In women FH, lipid-lowering interrupted during childbearing contraindication medication conception, pregnancy breastfeeding. However, little known about impact breastfeeding on lipid profile other risk markers for atherosclerotic cardiovascular disease (ASCVD) FH compared without...